{
    "clinical_study": {
        "@rank": "149860", 
        "arm_group": [
            {
                "arm_group_label": "DLBS1033", 
                "arm_group_type": "Experimental", 
                "description": "DLBS1033 tablet is administered at the dose of 490 mg, one tablet three times daily, every day for twelve weeks of study period"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo tablet is administered one tablet three times daily, every day for twelve weeks of study period"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a prospective, randomized, double-blind, double-dummy, and controlled study of\n      DLBS1033 for the improvement of ankle-brachial index in diabetic patients with peripheral\n      arterial disease (PAD). It is hypothesized that the addition of DLBS1033 on top of aspirin\n      treatment will augment significantly the resting ABI in diabetes patient with PAD in\n      comparison with that of aspirin alone."
        }, 
        "brief_title": "DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diabetes", 
            "Peripheral Arterial Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subjects in this study will be screened consecutively and eligible subjects will be\n      randomized to receive aspirin tablet 80 mg once daily and either the investigational drug,\n      DLBS1033 tablet 490 mg three times daily or its placebo.\n\n      Diabetic subjects who have been being under therapy with aspirin can directly start with\n      study treatment. For those who are currently not under therapy with aspirin, though, i.e.\n      newly-diagnosed diabetic subjects (with PAD) who have never been treated with aspirin, or\n      those who have been being treated with antiplatelet(s) other than aspirin, there will be a\n      run-in period during which they will receive (or be switched to) aspirin treatment, without\n      any other antiplatelets, for two weeks. After then, they will receive study medication.\n\n      Clinical and laboratory examinations to evaluate the investigational drug's efficacy and\n      safety will be performed at baseline and at the interval of six weeks over the twelve\n      week-course of therapy, while drug dispensing and accountability will be carried out at\n      interval of 3 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent before any trial related activities.\n\n          -  Male or female subjects of 40 - 65 years of age.\n\n          -  Diagnosis of diabetes mellitus defined as HbA1c level of \u2265 6.5% (for newly diagnosed\n             diabetes) or based on medical history.\n\n          -  Presence of peripheral arterial disease with resting ankle-brachial index (ABI) of\n             0.41-0.90 inclusive (i.e. mild to severe PAD, without critical limb ischemia).\n\n        (Note: the reference leg should be determined at this point. Henceforth, ABI improvement\n        will be based on measurement on the same leg as reference).\n\n          -  Able to take oral medication.\n\n          -  Patients or patients' legally acceptable representatives are able and willing to\n             record adverse events in a diary.\n\n          -  Patients or patients' legally acceptable representatives have the ability to comply\n             with the trial protocol.\n\n        Exclusion Criteria:\n\n          -  Females of childbearing potential: pregnancy, breast-feeding, and the intention of\n             becoming pregnant.\n\n          -  Recent stroke attack, myocardial infarction/unstable angina/acute coronary syndrome,\n             coronary artery bypass surgery (CABG) or percutaneous transluminal coronary\n             angioplasty (PTCA)/stent within 3 (three) months prior to screening.\n\n          -  Impaired liver function: serum ALT > 2.5 times upper limit of normal.\n\n          -  Impaired renal function: serum creatinine \u2265 1.5 times upper limit of normal.\n\n          -  Concomitant use of other antithrombosis drugs, such as oral anticoagulants,\n             dypiridamole, thienopyridines (such as clopidogrel), cilostazol or glycoprotein\n             IIb/IIIa antagonist or any antiplatelets other than the study medication.\n\n          -  Subjects with concurrent herbal (alternative) medicines or food supplements suspected\n             to have effect on hemostasis parameters.\n\n          -  Subjects with any other disease state, including chronic or acute systemic\n             infections, uncontrolled illnesses or other chronic diseases, which judged by the\n             investigator, could interfere with trial participation or trial evaluation.\n\n          -  Subjects with high risk of bleeding:\n\n               -  Subjects with history of acquired or congenital bleeding disorder, coagulopathy,\n                  or platelet disorder;\n\n               -  Subjects with evidence of active pathological bleeding or history of bleeding\n                  such as gastrointestinal or genitourinary bleeding unless the cause has been\n                  definitely corrected;\n\n               -  History or presence of intracranial bleeding or hemorrhagic retinopathy,\n                  unstable angina, severe valvular heart disease, severe anemia, suspected or\n                  known dissecting aneurysm, acute myocarditis or pericarditis, severe aortic\n                  stenosis, severe hypertrophic obstructive cardiomyopathy,\n\n               -  Severe or uncontrolled arterial hypertension (systolic blood pressure > 160\n                  mmHg, diastolic > 100 mmHg).\n\n          -  Subjects with prior experience with DLBS1033 or other oral lumbrokinase products.\n\n          -  Subjects with known or suspected allergy to any of study medications used in the\n             study, including other lumbrokinase products.\n\n          -  Subjects with known or suspected allergy or resistant to aspirin.\n\n          -  Subjects enrolled in other interventional protocol within 30 days prior to Screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "114", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 21, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02145988", 
            "org_study_id": "DLBS1033-0312"
        }, 
        "intervention": [
            {
                "arm_group_label": "DLBS1033", 
                "description": "Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period", 
                "intervention_name": "DLBS1033", 
                "intervention_type": "Drug", 
                "other_name": "Disolf"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "DLBS1033", 
            "Resting"
        ], 
        "lastchanged_date": "May 22, 2014", 
        "location": {
            "contact": {
                "email": "ksuas@yahoo.com", 
                "last_name": "Ketut Suastika, Prof, SpPD, MD", 
                "phone": "+62-361-227-911"
            }, 
            "facility": {
                "address": {
                    "city": "Denpasar", 
                    "country": "Indonesia", 
                    "state": "Bali"
                }, 
                "name": "Department of Internal Medicine, Faculty of Medicine, University of Udayana/Sanglah Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Wira Gotera, SpPD, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Gede B Tresna, SpPD, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Made P Dwipayana, SpPD, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Indonesia"
        }, 
        "number_of_arms": "2", 
        "official_title": "Improvement of Ankle-Brachial Index by DLBS1033 Treatment in Diabetic Patients With Peripheral Arterial Disease", 
        "overall_contact": {
            "email": "ksuas@yahoo.com", 
            "last_name": "Ketut Suastika, Prof, SpPD, MD", 
            "phone": "+62-361-227-911"
        }, 
        "overall_official": {
            "affiliation": "Department of Internal Medicine, Faculty of Medicine, University of Udayana/Sanglah Hospital", 
            "last_name": "Ketut Suastika, Prof, SpPD, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Indonesia: National Agency of Drug and Food Control", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The change of resting ABI", 
            "measure": "Resting ankle-brachial index (ABI)", 
            "safety_issue": "No", 
            "time_frame": "Week 0 and 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02145988"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The change of resting ABI", 
                "measure": "Resting ABI", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and 6"
            }, 
            {
                "description": "The change of hs-CRP", 
                "measure": "hs-CRP", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 6, and 12"
            }, 
            {
                "description": "The change of platelet aggregation", 
                "measure": "Platelet aggregation", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 6, and 12"
            }, 
            {
                "description": "The change of fibrinogen", 
                "measure": "Fibrinogen", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 6, and 12"
            }, 
            {
                "description": "The change of d-dimer", 
                "measure": "d-dimer", 
                "safety_issue": "No", 
                "time_frame": "Week 0, 6, and 12"
            }, 
            {
                "description": "The change of HbA1c", 
                "measure": "HbA1c", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and 12"
            }, 
            {
                "description": "The change of FPG", 
                "measure": "Fasting plasma glucose (FPG)", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and 12"
            }, 
            {
                "description": "The change of 2h-PG", 
                "measure": "2 hour post prandial glucose (2h-PG)", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and 12"
            }, 
            {
                "description": "The change of lipid profile: LDL, HDL, triglycerides, and total cholesterol", 
                "measure": "Lipid profile", 
                "safety_issue": "No", 
                "time_frame": "Week 0 and 12"
            }, 
            {
                "description": "ECG examination", 
                "measure": "Electrocardiography (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "Week 0, 6, and 12"
            }, 
            {
                "description": "Routine hematology measured includes: hemoglobin, hematocrit, RBC, WBC, differentiation of WBC, and platelet count", 
                "measure": "Routine hematology", 
                "safety_issue": "Yes", 
                "time_frame": "Week 0, 6, and 12"
            }, 
            {
                "description": "Liver function measured includes: serum ALT, AST, and alkaline phosphatase", 
                "measure": "Liver function", 
                "safety_issue": "Yes", 
                "time_frame": "Week 0 and 12"
            }, 
            {
                "description": "Renal function measured includes: serum creatinine and blood urea nitrogen (BUN)", 
                "measure": "Renal function", 
                "safety_issue": "Yes", 
                "time_frame": "Week 0 and 12"
            }, 
            {
                "description": "Haemostasis parameters measured includes: prothrombin time (PT) and activated partial thromboplastin time (aPTT)", 
                "measure": "Haemostasis parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Week 0, 6, and 12"
            }, 
            {
                "description": "Adverse events, including bleeding events, will be observed and carefully evaluated along the course of the study", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Week 0 - 12"
            }
        ], 
        "source": "Dexa Medica Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dexa Medica Group", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}